Antitumor treatment and cardiohemodynamics in patients with multiple myeloma depending on renal function
DOI:
https://doi.org/10.14739/2409-2932.2020.2.207199Keywords:
cardiohemodynamics, multiple myeloma, renal function, antitumor treatmentAbstract
Purpose – to evaluate the relations of antitumor treatment and cardiohemodynamics in patients with multiple myeloma depending on renal function.
Materials and methods. Fifty-one subjects with multiple myeloma were enrolled in the study. They were divided into groups depending on the glomerular filtration rate (GFR). First group involved 12 patients with GFR 30–59 ml/min/1,73 m2, second one – 14 patients with GFR 60–89 ml/min/1,73m2, third one – 25 patients with normal renal function. All patients underwent echocardiography before and after antitumor treatment.
Results. In patients with GFR 30–59 ml/min/1.73 m2 ejection fraction was significantly lower in comparing with healthy persons (54.70 [51.20; 57.60] % versus 59.82 [57.81; 62.29] %; P = 0.012) mainly due to decreased end systolic volume (ESV) (55.90 [43.28; 59.39] ml versus 34,22 [31.72; 41.24] ml; P = 0.031). In this group ESV was significantly lower in comparing with patients with normal renal function. In patients with GFR 30–59 ml/min/1.73 m2 after antitumor treatment E (0.77 [0.59; 0.81] m/c, E/A (0.91 [0.86; 0.95] m/c were significantly lower in comparing with dates before treatment (P < 0.05). In patients with GFR ≥90 ml/min/1,73 m2 after antitumor treatment E/A (0.89 [0.72; 1.11] m/c were significantly lower in comparing with dates before treatment (P < 0.05).
In patients with GFR 30–59 ml/min/1.73 m2 E (0.89 [0.75; 1.00] m/s versus 1.01 [1.02; 1.24]; P = 0.014), A (0.89 [0.77; 1.10] m/s versus 0.73 [0.56; 0.85] м/s; P = 0.020). E/A (0.98 [0.94;1.12] versus 1.16 [1.06; 1.25]; P = 0.011) were significantly lower in in comparing with control.
Global circular systolic strain (-17.60 [-21.05; -15.18] versus -25.92 [-26.09; -19.15]; P = 0.012) and global circular systolic strain rate (-1.22 [-1.32; -1.20] versus -1.32 [-1.42; ‑1.25]; P = 0.022) was significantly lower in group of patients with GFR 30–59 ml/min/1.73 m2 in comparing with healthy persons.
Conclusions. Our data suggest that the extent of renal function is directly associated with left ventricle diastolic and regional systolic parameters. Among patients with multiple myeloma and renal insufficiency systolic, diastolic, and regional systolic contractility were significantly worse in comparing with patients with normal renal function and healthy persons. Antitumor treatment of multiple myeloma has a negative effect on diastolic and regional systolic function. These dates may be used for the prognosis of cardiovascular events.
References
Cowan, A. J., Allen, C., Barac, A., Basaleem, H., Bensenor, I., Curado, M. P., … Fitzmaurice, C. (2018). Global Burden of Multiple Myeloma ASystematic Analysis for the Global Burden of Disease Study 2016. Jama Oncology, 4(9), 1221-1227. https://doi.org/10.1001/jamaoncol.2018.2128
De Stefano, V., Za, T., & Rossi, E. (2014). Venous Thromboembolism in Multiple Myeloma. Seminars in Thrombosis and Hemostasis, 40(3), 338-347. https://doi.org/10.1055/s-0034-1370793
Kuznetsova, L. P., & Panasenko, M. O. (2019). Komorbidna patolohiia u khvorykh na mnozhynnu miielomu [Comorbidities in patients with multiple myeloma]. Current issues in pharmacy and medicine: science and practice, (2), 222-227. https://doi.org/10.14739/2409-2932.2019.2.171245
Samura, B. B. (2015). Prognosticheskaya rol’ tsirkuliruyushchego galektina-3 u patsientov s mnozhestvennoi mielomoi v remissii [Predictive value of circulating galectin-3 in patients with multiple myeloma in remission]. Zaporozhye medical journal, (4), 11-16. https://doi.org/10.14739/2310-1210.2015.4.50298
Eleutherakis-Papaiakovou, V., Bamias, A., Gika, D., Simeonidis, A., Pouli, A., Anagnostopoulos, A., Michali, E., Economopoulos, T., Zervas, K., Dimopoulos, M. A., & Greek Myeloma Study Group (2007). Renal failure in multiple myeloma: incidence, correlations, and prognostic significance. Leukemia & lymphoma, 48(2), 337-341. https://doi.org/10.1080/10428190601126602
Dimopoulos, M. A., Kastritis, E., Rosinol, L., Bladé, J., & Ludwig, H. (2008). Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia, 22(8), 1485-1493. https://doi.org/10.1038/leu.2008.131
Dimopoulos, M. A., Sonneveld, P., Leung, N., Merlini, G., Ludwig, H., Kastritis, E., Goldschmidt, H., Joshua, D., Orlowski, R. Z., Powles, R., Vesole, D. H., Garderet, L., Einsele, H., Palumbo, A., Cavo, M., Richardson, P. G., Moreau, P., San Miguel, J., Rajkumar, S. V., Durie, B. G., … Terpos, E. (2016). International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34(13), 1544-1557. https://doi.org/10.1200/JCO.2015.65.0044
Ministry of Health of Ukraine. (2015, November 2). Unifikovanyi klinichnyi protokol pervynnoi, vtorynnoi (spetsializovanoi), tretynnoi (vysokospetsializovanoi) medychnoi dopomohy. Mnozhynna miieloma : Nakaz MOZ Ukrainy 02.11.2015 No. 710 [Unified clinical protocol of primary, secondary (specialized), tertiary (highly specialized) medical care. Multiple myeloma (No. 710)]. https://dec.gov.ua/wp-content/uploads/images/dodatki/2015_710_MM/2015_710_YKPMD_MM.pdf
Flakskampf, F. A. (Ed.). (2013). Prakticheskaya ekhokardiografiya : rukovodstvo po ekhokardiograficheskoi diagnostike [Practical echocardiography]. Moscow : MEDpress-inform. [in Russian].
Lapach, S. N., Chubenko, A. V., & Babich, P. N. (2002). Statistika v nauke i biznese [Statistics in science and business]. Kiev: Morion. [in Russian].
Gavriatopoulou, M., Musto, P., Caers, J., Merlini, G., Kastritis, E., van de Donk, N., Gay, F., Hegenbart, U., Hajek, R., Zweegman, S., Bruno, B., Straka, C., Dimopoulos, M. A., Einsele, H., Boccadoro, M., Sonneveld, P., Engelhardt, M., & Terpos, E. (2018). European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. Leukemia, 32(9), 1883-1898. https://doi.org/10.1038/s41375-018-0209-7
Downloads
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
